Cover Potential of CAR-T Therapy and the Myeloma Patient Journey

 

The Potential of CAR-T Therapy and the Myeloma Patient Journey

Discussion with the IMF’s
Nurse Leadership Board
September 28, 2018 | Las Vegas

 

In September 2018, members of the IMF’s Nurse Leadership Board (NLB) who have experience with CAR-T therapy convened to discuss anti-B cell Maturation Antigen (BCMA) in the relapsed/refractory multiple myeloma patient-treatment journey. In this paper, the NLB provides insights and education about CAR T-cell therapy. Read the full publication now.


 

 

Steroid-Associated Side Effects

Clinical Journal of Oncology Nursing
Volume 21, Issue 2

 

 

Background: One constant and relatively unchanged aspect of treatment of multiple myeloma (MM) is the use of glucocorticosteroids, or steroids, which can cause a wide range of adverse side effects and harm patients’ quality of life.

Objectives: The objective of this study was to provide updated recommendations on the management of steroid-associated side effects in patients with MM.

Methods: A study of steroid-associated side effects in MM treatment regimens was reviewed to provide updated recommendations to healthcare professionals.

Findings: Identifying the side effects of steroids and managing them promptly contribute to the success of steroid-containing regimens for patients with MM.

CJON 2017, 21(2), 240-249 DOI: 10.1188/17.CJON.240-249


 

 

The Current Therapeutic Landscape and the Patient Experience

view document

 

On December 2, 2016, 7 members of the International Myeloma Foundation (IMF) Nurse Leadership Board convened in San Diego, California, in concurrence with the American Society of Hematology (ASH) Annual Meeting, to discuss the following topics as they relate to the current therapeutic landscape and the patient experience: 

  1.  Current therapeutic landscape 
  2.  Patient challenges and education opportunities 
  3.  Unmet needs and best practices for patient care
  4.  Potential solutions to overcoming barriers and optimizing care  

 

 

The Advanced Practitioner's Guide to Multiple Myeloma

JADPRO Vol. 7 | Supplement 1 | March 2016

 

 

Published in the Journal of the Advanced Practitioner in Oncology (JADPRO), this guide is a continuing education activity for health-care professionals. It provides the latest scientific information on effectively managing the care of multiple myeloma patients.

  1.  The Continuum of Care in Multiple Myeloma Redefined: Challenges and Opportunities
  2.  Sequencing of Treatment and Integration of Clinical Trials
  3.  Palliative Care in Multiple Myeloma
  4.  New Agents in the Treatment of Multiple Myeloma
  5.  Monoclonal Antibodies in the Treatment of Multiple Myeloma
  6.  Updates in the Diagnosis and Monitoring of Multiple Myeloma
  7.  Adherence, Persistence, and Treatment Fatigue in Multiple Myeloma
  8.  Resources for Patients and Caregivers With Multiple Myeloma and Their Providers
  9.  Multiple Myeloma Treatment Options for Newly Diagnosed, Relapsed, and Refractory Disease

 

Survivorship Care Plan for Multiple Myeloma

CJON  | Supplement to Vol. 15 Num. 4 | August 2011

 

 

Patients with myeloma are surviving longer and, therefore, may experience continuing effects of their disease and treatment. Through clinical experience, the International Myeloma Foundation Nurse Leadership Board (NLB) was aware that a specific set of needs exists in this patient population. Identification of these needs, and stressing the importance of prompt intervention, could lead to improvement in their quality of life and overall survival. 

  1.  Survivorship Care Guidelines for Patients Living With Multiple Myeloma
  2. Maintaining Bone Health in Patients With Multiple Myeloma
  3. Routine Health Maintenance in Patients Living With Multiple Myeloma
  4. Mobility and Safety in the Multiple Myeloma Survivor
  5. Sexual Dysfunction in Multiple Myeloma
  6. Renal Complications in Multiple Myeloma and Related Disorder

 

Side Effects of Novel Agents Fact Sheets

CJON | Supplement to Vol. 12 Num. 3 | June 2008

 

 

Managing the patient with multiple myeloma (MM) across the continuum of care is challenging given the heterogeneity of the population. Provided are IMF Patient Education Tools. These fact sheets discuss side effects that may result from the use of novel agents in multiple myeloma, and how to manage those side effects.

  1.  Managing Steroid-Associated Side Effect of Novel Agents for Multiple Myeloma
  2. Preventing Peripheral Neuropathy From Novel Agents for Multiple Myeloma
  3. Managing Myelosuppression from Novel Agents for Multiple Myeloma
  4. Managing Gastrointestinal Side Effects of Novel Agents for Multiple Myelma
  5. Preventing Blood Clots and Thromoembolic Events with Novel Agents for Multiple Myeloma

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.